application of targeted drug into super selective intraarterial chemotherapy on oral cancer

• Project/Area Number: 15K20550
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Surgical dentistry
• Research Institution: Yokohama City University
• Principal Investigator: MITSUNAGA Sachiyo 横浜市立大学, 医学研究科, 共同研究員 (20567606)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000); Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000); Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 口腔癌治療 / 分子標的薬

Outline of Final Research Achievements

To develop the optimized chemotherapy, we investigate the several combination of chemo-drugs including cetuximab and different routes of drug administration. We determined the anti-tumor effect of docetaxel and cetuximab with or without combination using different routes including intratumoral (IT) as locally and intraperitoneal (IP) as systemic administration. Co-administration of cetuximab (IP) and docetaxel (IT) showed the highest anti-tumor effect and decreased density of microvessel in tumor. Although administration of docetaxel induced the influx of CD11b+ cells, IP administration of cetuximab inhibited the recruitment of CD11b+ cells that may contribute to neovasculogenesis.